Please use this identifier to cite or link to this item: http://dora.health.qld.gov.au/qldresearchjspui/handle/1/745
Title: CoMET: a protocol for a randomised controlled trial of co-commencement of METformin as an adjunctive treatment to attenuate weight gain and metabolic syndrome in patients with schizophrenia newly commenced on clozapine
Authors: Suetani, S. 
Kisely, S. 
Sardinha, S. 
McGrath, J. J. 
Moudgil, V. 
Patterson, S. 
Winckel, K. 
Lim, C. 
Stedman, T. 
Siskind, D. 
Flaws, D. 
Baker, A. 
Friend, N. 
Russell, A. 
Issue Date: 2018
Source: BMJ open Mar 2 8, (3), 2018, p. e021000
Pages: e021000
Journal Title: BMJ open
Journal: BMJ Open
Abstract: INTRODUCTION: Clozapine, while effective in treatment refractory schizophrenia, is associated with significant weight gain, heart disease and increased risk of type 2 diabetes mellitus (T2DM). Although there is evidence for weight loss with metformin for people with obesity who are already taking clozapine, there have been no published trials that have investigated the effect of metformin in attenuating weight gain at the time of clozapine initiation. METHODS AND ANALYSIS: A 24-week double-blind placebo-controlled trial of concomitant prescription of metformin at clozapine commencement. Eighty-six people being commenced on clozapine will be randomised to placebo or metformin (variable dose, up to 2 g/day). The primary outcome is comparative end point body weight, between the placebo and metformin groups. Secondary outcomes are comparative rates of conversion to T2DM, alteration of metabolic syndrome parameters, proportion gaining >5% body weight and changes in diet and appetite. We will additionally examine biomarkers associated with change in weight among trial participants. ETHICS AND DISSEMINATION: Ethics approval was granted by the Metro South Human Research Ethics Committee HREC/17/QPAH/538-SSA/17/QPAH/565. We plan to submit a manuscript of the results to a peer-reviewed journal, and present results at conferences, consumer forums and hospital grand rounds. TRIAL REGISTRATION NUMBER: ACTRN12617001547336; Pre-results.2044-6055Siskind, Dan
Orcid: 0000-0002-2072-9216
Friend, Nadia
Russell, Anthony
McGrath, John J
Lim, Carmen
Patterson, Sue
Flaws, Dylan
Stedman, Terry
Moudgil, Vikas
Sardinha, Savio
Suetani, Shuichi
Kisely, Steve
Winckel, Karl
Baker, Andrea
Journal Article
Research Support, Non-U.S. Gov't
England
BMJ Open. 2018 Mar 2;8(3):e021000. doi: 10.1136/bmjopen-2017-021000.
DOI: 10.1136/bmjopen-2017-021000
BMJ open
31
Keywords: *clozapine*diabetes;*metabolic syndrome;*obesity;*schizophrenia;AstraZeneca, Boehringer Ingelheim, Eli Lilly, MSD, Novo Nordisk and Sanofi and;has participated on advisory panels for MSD and Novo Nordisk.
Type: Article
Appears in Collections:Publications

Files in This Item:
3 files
File Description SizeFormat 
Siskind 2018.pdf615.43 kBAdobe PDF
Download Adobe
Thumbnail
View/Open

Page view(s)

106
checked on Dec 7, 2019

Download(s)

10
checked on Dec 7, 2019

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.